Concepedia

Daniela Piani-Meier

DP

Statistics

Publications

9

Citations

312

H-Index

9

Active since

2018

Affiliations

Novartis (Switzerland)(Current)

Queen Mary University of London

Université de Lille

Cleveland Clinic

University Hospital Carl Gustav Carus

Daniela Piani-Meier is an author at Novartis (Switzerland) specializing in risk, epidemiology, and clinical epidemiology.

ORCID

Top concepts

Publications per year

2018–2022

9

Publications

9

Predicting risk of secondary progression in multiple sclerosis: A nomogram

Ali Manouchehrinia, Feng Zhu, Daniela Piani-Meier et al. · Multiple Sclerosis Journal · 2018 · 77 citations

, , +13

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

Tjalf Ziemssen, Daniela Piani-Meier, Bryan Bennett et al. · Journal of Medical Internet Research · 2020 · 53 citations · Full text

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Bruce Cree, Douglas L. Arnold, Robert J. Fox et al. · Multiple Sclerosis Journal · 2022 · 44 citations · Full text

A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians’ and patients’ views

Tjalf Ziemssen, Chloe Tolley, Bryan Bennett et al. · Multiple Sclerosis and Related Disorders · 2019 · 40 citations · Full text

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

Douglas L. Arnold, Daniela Piani-Meier, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2022 · 32 citations · Full text

1–5 of 9